Pfizer’s Bosulif Too Expensive And Lacks Data, Says NICE

16 Jul 2013

• By Faraz Kermani

NICE has rejected Bosulif for leukemia principally on cost grounds, but also due to a lack of comprehensive long-term data, which is also being sought by the EMA.

Pfizer Inc. is either going to have to come up with the additional information required by the European Medicines Agency for its myeloid leukemia therapy Bosulif (bosutinib) marketing authorization, or cut the drug’s price by a third if it is going to satisfy the U.K. reimbursement watchdog, NICE.

Bosulif has a “conditional” central marketing authorization from the EMA for the treatment of Philadelphia chromosome-positive chronic, accelerated or blast...